​Principal Investigator: Dr. Zhuoer Xie

Disease: Clonal Hematopoiesis

Research Description: Clonal hematopoiesis (CH), or abnormal growth of certain blood cells, increases the risk of developing blood cancers, as well as heart disease and kidney issues. There are currently no effective treatments for CH. Recent studies have shown that empagliflozin, primarily used in type 2 diabetes, has improved blood levels in heart failure patients, with additional protective benefits to the heart and kidney. This open label, Phase II clinical trial evaluates the benefit of empagliflozin in non-diabetic CH patients, and if successful, could point to the first effective therapy in CH.

Funding Partners: Goldman Philanthropic Partnerships and the David and Susan Sherman Philanthropic Fund

Initial CWR Funding Role: Supplemental